GlaxoSmithKline and Vir aim to take on Covid-19 with antibodies and CRISPR
The drug giant GlaxoSmithKline said Monday it will collaborate with Vir Biotechnology on experimental treatments and potentially, vaccines against the novel coronavirus.
As part of the deal, GlaxoSmithKline will invest $250 million in the San Francisco startup at a 10% premium to the company’s closing share price on Friday.
Read Original Article: GlaxoSmithKline and Vir aim to take on Covid-19 with antibodies and CRISPR »
